|L20003||1mg/well * 741 Compounds||Inquiry||In stock|| |
|L20003||100uL/well (10mM solution) * 741 Compounds||Inquiry||In stock|
|Manufacturer||Wuhan ChemFaces Biochemical Co., Ltd.|
|Container||96 Well Format Sample|
|Storage||Protected from air and light, refrigerate or freeze(2-8 °)|
|Shelf Life||24 months (2-8 °)|
|Intended Use||For research use only. Not for human use. Not sell to patients|
|1. The products in the ChemFaces screening libraries are all from plants.|
|2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research.|
|3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools.|
|4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity.|
|5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution).|
Schisandrol A may be a new promising treatment for neurotoxicity, erectile dysfunction and cardiovascular disease.It can inhibit the activities of Pgp,Beta Amyloid,CYP3A4,cGMP,and NOS, the IC(50) value of CYP3A4 is 32.02 microM.
4-Hydroxybenzaldehyde shows an inhibitory effect on the GABA transaminase to contribute to an antiepileptic and anticonvulsive activity, and its inhibitory activity was higher than that of valproic acid, a known anticonvulsant.
Bakuchiol possesses anti-tumor, cytotoxic, anti-bacterial , and anti-helmenthic properties, it shows DNA polymerase1 inhibiting activity. Bakuchiol has great potential for use in food additives and mouthwash for preventing and treating dental caries.
|CFN99060||Quinovic acid 3-O-alpha-L-rhamnopyranoside
Quinovic acid 3-O-alpha-L-rhamnopyranoside shows significant inhibitory activity against snake venom phosphodiesterase-I.
Ganoderol B is a potent α-glucosidase and angiotensin-converting enzyme inhibitor, with an IC(50) of α-glucosidase is 119.8 uM. It may be useful in prostate cancer and benign prostatic hyperplasia (BPH) therapy through suppressing the function of androgen and its receptor.
Ganoderol A has significant anti-inflammatory activity and protection against UVA damage. it has an inhibitory effect on angiotensin converting enzyme activity and cholesterol biosynthesis.
2-(3,4-Dihydroxyphenyl)ethanol has antioxidant properties; it is a potent specific inhibitor of lipoxygenase activities, it inhibits platelet 12-LO activity (IC50, 4.2 microM) and PMNL 5-LO activity (IC50, 13 microM) but not cyclooxygenase activity in cell-free conditions; it also inhibits 12-LO activity in intact platelets (IC50, 50 microM) and reduces leukotriene B4 production in intact PMNL stimulated by A23187 (IC50, 26 microM).
Squalene, a naturally occurring substance found in plants, animals and humans, is a component of some adjuvants that is added to vaccines to enhance the immune response.Squalene shows several pharmacological properties such as hypolipidemic, hepatoprotective, cardioprotective, antioxidant, and antitoxicant activity. Squalene can significantly suppress colonic aberrant crypt foci (ACF) formation and crypt multiplicity strengthens the hypothesis that squalene possesses chemopreventive activity against colon carcinogenesis.
7,3',4'-Trihydroxy-3-benzyl-2H-chromene is a potential xanthine oxidase inhibitor.
Adenanthin is a novel NF-κB and nucleophilic cysteines inhibitor, it has bacteriostatic, antiinflammatory, and antitumour activities. Adenanthin also has antileukemic activity through targeting peroxiredoxin I/II. Adenanthin can serve as the development of Prx I– and Prx II–targeted therapeutic agents.